A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| AZD1080 | AZD1080 is a brain-permeable GSK3 inhibitor with Ki values of 6.9 nM and 31 nM for GSK3α and GSK3β, respectively. Study showed that AZD1080 inhibited tau phosphorylation in cells. It also suppresses ovarian cancer cell proliferation, invasion, migration, and lamellipodia formation, and induces G1 arrest. Synonyms: AZD-1080; 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carbonitrile. Grades: >98%. CAS No. 612487-72-6. Molecular formula: C19H18N4O2. Mole weight: 334.37. |  |
| AZD1080 | AZD1080 Inhibitor. Uses: Scientific use. Product Category: T1741. CAS No. 612487-72-6. |  |
| AZD1152-HQPA | Barasertib is a potent and highly selective inhibitor of AURKB with IC50 of 0.37 nM, acting via preventing the transfer of the phosphate group from the ATP molecule to AURKB substrates. The present study demonstrated for the first time, that AURKB inhibition interferes with early regeneration of SGs. Barasertib has been demonstrated that it is 3,700-fold greater selectivity than Aurora A. Synonyms: INH 34; AZD1152-HQPA; AZD2811. Grades: ≥98%. CAS No. 722544-51-6. Molecular formula: C26H30FN7O3. Mole weight: 507.56. | |
| AZD1152, TFA Salt | An Aurora kinase inhibitor, used to treat patients with advanced solid tumors. Group: Biochemicals. Alternative Names: 3-[[7-[3-[Ethyl[2- (phosphonooxy) ethyl]amino]propoxy]-4-quinazolinyl]amino]-N- (3-fluorophenyl) -1H-pyrazole-5-acetamide Trifluoroacetic Acid Salt; Barasertib Trifluoroacetic Acid Salt; AZD-1152 Trifluoroacetic Acid Salt. Grades: Highly Purified. CAS No. 957881-03-7. Pack Sizes: 1mg, 5mg, 10mg. Molecular Formula: C??H??FN?O?P; x(C ?HF?O?), Molecular Weight: 587.54. US Biological Life Sciences. |  Worldwide |
| AZD1208 | AZD1208 is an orally bioavailable, highly selective PIM kinases inhibitor [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1204144-28-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-15604. |  |
| AZD-1208 | AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity. AZD1208 inhibits the activities of PIM1, PIM2 and PIM3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition. Synonyms: AZD1208; AZD 1208. Grades: 0.98. CAS No. 1204144-28-4. Molecular formula: C21H21N3O2S. Mole weight: 379.478. | |
| AZD1283 | AZD1283 dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg/kg/min, respectively. The doses that induced a larger than 3-fold increase in bleeding time were 33 and 100 μg/kg/min for 3 and 13, respectively. Thus, the therapeutic index (TI) was ≥10 for both compounds. On the basis of these data, compound 3 was progressed into human clinical trials as candidate drug AZD1283. Synonyms: AZD 1283; AZD-1283. Grades: 0.98. CAS No. 919351-41-0. Molecular formula: C23H26N4O5S. Mole weight: 470.544. | |
| AZD1305 | AZD1305 is a potassium channel and sodium channel antagonist. It can inhibit rapidly the activating delayed-rectifier potassium current, L-type calcium current, and inward sodium current. Phase II clinical trials for Arrhythmias, Atrial fibrillation, Atrial flutter and Left ventricular dysfunction were discontinued. Uses: Arrhythmias; atrial fibrillation; atrial flutter; left ventricular dysfunction. Synonyms: AZD-1305; AZD 1305; AZD1305; UNII-CZO834LXQM; UNII-CZO834LXQM; (2-(7-(2-(4-Cyano-2-fluorophenoxy)ethyl)-9-oxa-3,7-diazabicyclo(3.3.1)non-3-yl)ethyl)carbamic acid tert-butyl ester. Grades: 98%. CAS No. 872045-91-5. Molecular formula: C22H31FN4O4. Mole weight: 434.51. | |
| azd1390 | azd1390 Inhibitor. Uses: Scientific use. Product Category: T5175. CAS No. 2089288-03-7. | |
| AZD1390 | AZD1390 is a first-in-class, orally available and CNS penetrant ATM inhibitor with an IC50 of 0.78 nM in cells and >10,000-fold selectivity over closely related members of the PIKK family of enzymes and excellent selectivity across a broad panel of kinases. It can be used to cross the blood-brain barrier suitable for the treatment of intracranial malignancies. Synonyms: AZD-1390; AZD 1390. Grades: ≥98%. CAS No. 2089288-03-7. Molecular formula: C27H32FN5O2. Mole weight: 477.57. | |
| AZD1390 | AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC 50 of 0.78 nM in cell [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2089288-03-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109566. | |
| AZD1480 | AZD1480 is a novel ATP-competitive inhibitor of JAK1 and JAK2 with IC50 of 1.3nM and 0.26nM, respectively. Group: Biochemicals. Alternative Names: (S)-5-chloro-N2-(1-(5-fluoropyrimidin-2-yl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine. Grades: Highly Purified. Pack Sizes: 1mg, 5mg. US Biological Life Sciences. | Worldwide |
| AZD-1480 | AZD1480 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. AZD1480 inhibits JAK2 activation, leading to the inhibition of the JAK/STAT (signal transducer and activator of transcription) signaling including activation of STAT3. Synonyms: AZD1480; AZD-1480; AZD 1480. Grades: 0.98. CAS No. 935666-88-9. Molecular formula: C14H14ClFN8. Mole weight: 348.77. | |
| AZD1656 | AZD1656 is a potent, selective and orally active glucokinase activator with an EC 50 of 60 nM. AZD1656 has the potential for type 2 diabetes research [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 919783-22-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15675. | |
| AZD1979 | This active molecular is a MCHr1 (melanin concentrating hormone receptor 1) antagonist originated by AstraZeneca. AZD1979 has excellent DMPK properties and gave good effects on weight loss in animal model. In Jul 2014, AstraZeneca terminated a phase I trial in Obesity in healthy volunteers in USA after stopping criteria were reached. Uses: Obesity. Synonyms: AZD1979; AZD-1979; AZD 1979. (3-(4-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone. Grades: 98%. CAS No. 1254035-84-1. Molecular formula: C25H26N4O5. Mole weight: 462.51. | |
| AZD1981 | AZD1981, as a potent antagonist in a disease relevant cell system, inhibits DK-PGD2-induced CD11b expression in human eosinophils with IC50 of 10 nM. Synonyms: AZD1981; AZD 1981; AZD-1981. Grades: 98%. CAS No. 802904-66-1. Molecular formula: C19H17ClN2O3S. Mole weight: 388.866. | |
| AZD1981 | AZD1981 is a potent and selective CRTh2 antagonist; displaces radio-labelled PGD2 from human recombinant DP2 with high potency (pIC50 = 8. Uses: Scientific research. Group: Signaling pathways. CAS No. 802904-66-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15950. | |
| AZD-2014 | AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. AZD2014 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. Synonyms: AZD2014, AZD-2014, AZD 2014, Vistusertib. Grades: 0.98. CAS No. 1009298-59-2. Molecular formula: C25H30N6O3. Mole weight: 462.554. | |
| AZD 2066 | AZD 2066 is a mGluR5 anatagonist. It displays discriminative effects in rats. It is brain penetrant and orally bioavailable. It is used to prevent and treat pain, psychiatric, neurological and other diseases. Synonyms: AZD 2066; AZD2066; AZD-2066; 4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine. Grades: ≥98% by HPLC. CAS No. 934282-55-0. Molecular formula: C19H16ClN5O2. Mole weight: 381.82. | |
| AZD 2066 | AZD-2066 is a selective, orally active and blood-brain barrier-permeating mGluR5 antagonist. AZD 2066 activates the BDNF/trkB signaling pathway. AZD 2066 can be used in the research of neuropathic pain, major depressive disorder and gastroesophageal reflux disease [1] [2] [3] [5]. Uses: Scientific research. Group: Signaling pathways. CAS No. 934282-55-0. Pack Sizes: 1 mg; 5 mg. Product ID: HY-110255. | |
| AZD 2098 | AZD 2098 is a potent and selective CCR4 receptor antagonist (pIC50 = 7.8) used for the treatment of allergic rhinitis. CCR4 is a molecule that can drive the immune cells toward the tumor cells. Uses: The treatment of allergic rhinitis and asthma. Synonyms: AZD-2098; AZD 2098; AZD2098; 2,3-dichloro-N-(3-methoxypyrazin-2-yl)benzenesulfonamide. Grades: 99%. CAS No. 566203-88-1. Molecular formula: C11H9Cl2N3O3S. Mole weight: 334.18. | |
| AZD-2461 | AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein. AZD2641 is currently in Phase I clinical study. The study is being conducted to see how it may work to treat solid tumors. The study will also assess the blood levels and action of AZD2461 in the body over a period of time and will indicate whether the drug has a therapeutic effect on solid tumors. Synonyms: AZD2461; AZD 2461. Grades: 0.98. CAS No. 1174043-16-3. Molecular formula: C22H22FN3O3. Mole weight: 395.434. | |
| AZD2716 | AZD2716 is a potent sPLA2 inhibitor (IC50 = 10, 40, and 400 nM for sPLA2-IIa, -V, and -X, respectively). When incubated with HepG2 cells, AZD2716 effectively inhibited sPLA2 activity (IC50 value of <14 nM) and suppressed production of sPLA2-IIa (IC50 = 176 nM). Synonyms: AZD2716; AZD-2716; AZD 2716. (2R)-3-[3-(5-benzyl-2-carbamoylphenyl)phenyl]-2-methylpropanoic acid. Grades: 99%. CAS No. 1845753-81-2. Molecular formula: C24H23NO3. Mole weight: 373.44. | |
| AZD2858 | AZD2858 is a potent and selective GSK3β inhibitor with Ki value of 4.9 nM. It was shown to promote osteoblast differentiation in human adipose-derived stem cells (hADSC) in vitro. Synonyms: AZD-2858; 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide. Grades: >98%. CAS No. 486424-20-8. Molecular formula: C21H23N7O3S. Mole weight: 453.52. | |
| AZD 2858 hydrochloride | The hydrochloride salt form of AZD 2858. AZD 2858 is a potent and selective Glycogen Synthase Kinase-3β (GSK-3β; Ki = 4.9 nM) inhibitor used for Alzheimer's disease therapy with good BBB permeability in a bovine endothelial cell assay. AZD 2858 selectively inhibits GSK-3β-mediated tau phosphorylation (IC50 = 76 nM) in vitro. In rats, oral AZD2858 treatment caused a dose-dependent increase in trabecular bone mass by GSK-3 mediated inhibition of Wnt canonical signaling, making AZD2858 a possible therapeutic candidate for osteoporosis. Uses: The treatment of alzheimer's disease. Synonyms: AZD 2858 hydrochloride; AZD2858 hydrochloride; AZD-2858 hydrochloride; 3-amino-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide hydrochloride. Grades: 98%. CAS No. 486424-21-9. Molecular formula: C21H23N7O3S.HCl. Mole weight: 489.98. | |
| AZD2932 | AZD2932 is a new quinazoline ether inhibitor and is a high affinity inhibitor of VEFGR-2 and PDGFR. It has a balanced ~1:1 ratio of activity vs both VEGFR-2 and PDGFR&beta. It is also active on c-Kit and FLT3 with good selectivity on a panel of kinases. Synonyms: AZD2932; AZD 2932; AZD-2932. Grades: >98%. CAS No. 883986-34-3. Molecular formula: C24H25N5O4. Mole weight: 447.49. | |
| AZD-3147 | AZD-3147 is an extremely potent and selective dual inhibitor of mTORC1 and mTORC2. It exhibits >300-fold selectivity for mTOR over PI 3-kinase isoforms. It has physicochemical and pharmacokinetic properties suitable for development as a potential clinical candidate. Uses: Azd-3147 has physicochemical and pharmacokinetic properties suitable for development as a potential clinical candidate. Synonyms: AZD3147; AZD-3147; AZD 3147; (S)-1-(4-(4-(1-(cyclopropylsulfonyl)cyclopropyl)-6-(3-methylmorpholino)pyrimidin-2-yl)phenyl)-3-(2-hydroxyethyl)thiourea. Grades: >98%. CAS No. 1101810-02-9. Molecular formula: C24H31N5O4S2. Mole weight: 517.66. | |
| AZD-3161 | AZD 3161 is a Nav1.7-voltage-gated-sodium-channel-inhibitor originated by AstraZeneca. Phase-I clinical trials in Pain and Neuropathic pain was discontinued. Uses: Neuropathic pain; pain. Synonyms: UNII-403N302X2Y; CHEMBL2069427; 403N302X2Y; 1369501-46-1; AZD-3161; AZD3161; AZD 3161; SCHEMBL873691;N-[(3S)-5-(5-methoxypyrazin-2-yl)-3,4-dihydro-2H-chromen-3-yl]-6-(2,2,2-trifluoroethoxymethyl)pyridine-3-carboxamide. Grades: 98%. CAS No. 1369501-46-1. Molecular formula: C23H21F3N4O4. Mole weight: 474.44. | |
| AZD3229 | AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. It selectively inhibits growth of c-Kit mutant with GI50s of 1971 nM and PDGFR mutant with GI50s of 122 nM). AZD3229 demonstrates excellent cross-species pharmacokinetics, shows strong pharmacodynamic inhibition of target, and is active in several in vivo models of GIST. Synonyms: AZD-3229; AZD 3229; N-{4-[(6,7-dimethoxyquinazolin-4-yl)oxy]phenyl}-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide. Grades: ≥98%. CAS No. 2248003-60-1. Molecular formula: C24H26FN7O3. Mole weight: 479.51. | |
| AZD3229 | AZD3229 is a potent pan- KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. AZD3229 inhibits c-KIT with an IC 50 value of 223.3 nM [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2248003-60-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112802. | |
| AZD3229 Tosylate | AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. Uses: Scientific research. Group: Signaling pathways. CAS No. 2248003-71-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112802A. | |
| AZD3264 | AZD3264 is a novel IKK2 inhibitor. Synonyms: AZD 3264; AZD-3264; AZD3264. Grades: 98%. CAS No. 1609281-86-8. Molecular formula: C21H23N5O4S. Mole weight: 441.5. | |
| AZD3293 | AZD3293, a spiro compound, has been found to be a β-secretase inhibitor that has good blood-brain barrier penetration and could probably be significant in studies of Alzheimer's disease. It was just planed a Phase III trial in several areas. IC50: 0.2 nM. Synonyms: AZD-3293; AZD 3293; AZD3293; LY3314814; GTPL7789; LY 3314814; GTPL 7789; LY-3314814; GTPL-7789; SCHEMBL9948271; (1r,4r)-4-methoxy-5''-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine. Grades: 98%. CAS No. 1628076-74-3. Molecular formula: C26H28N4O. Mole weight: 412.53. | |
| AZD-3293 | AZD-3293. Uses: For analytical and research use. Group: Impurity standards. CAS No. 1383982-64-6. Molecular Formula: C26H28N4O. Mole Weight: 412.54. Catalog: APB1383982646. |  |
| AZD-3409 | AZD-3409 is a potent prenyl transferase inhibitor. AZD-3409 showed higher potency than lonafarnib. AZD3409 inhibits farnesylation to a higher extent than geranylgeranylation. AZD3409 might be active in gefitinib-resistant breast carcinoma. Synonyms: AZD-3409; AZD 3409; AZD3409. Grades: 98%. CAS No. 345915-10-8. Molecular formula: C34H41FN4O4S2. Mole weight: 652.844. | |
| AZD3463 | AZD3463. Group: Biochemicals. Alternative Names: N-(4-(4-Aminopiperidin-1-yl)-2-methoxyphenyl)-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine. Grades: Highly Purified. Pack Sizes: 1mg. Molecular Formula: C24H25ClN6O, Molecular Weight: 448.95. US Biological Life Sciences. | Worldwide |
| AZD-3463 | AZD-3463 is a potent ALK/IGF1R inhibitor with potential anticancer activity. Synonyms: AZD 3463; AZD3463. Grades: 0.98. CAS No. 1356962-20-3. Molecular formula: C24H25ClN6O. Mole weight: 448.95. | |
| AZD-3514 | AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. Removal of the basic piperazine nitrogen atom, introduction of a solubilising end group and partial reduction of the triazolopyridazine moiety in the previously-described lead androgen receptor downregulator 6-[4-(4-cyanobenzyl)piperazin-1-yl]-3-(trifluoromethyl)[1, 2, 4]triazolo[4, 3-b]pyridazine (1) addressed hERG and physical property issues, and led to clinical candidate 6- (4-{4- [2- (4-acetylpiperazin-1-yl) ethoxy] phenyl}piperidin-1-yl) -3- (trifluoromethyl) -7, 8-dihydro [1, 2, 4] triazolo [4, 3-b] pyridazine (12), designated AZD3514, that is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer. Group: Biochemicals. Alternative Names: 1- (4- (2- (4- (1- (3- (trifluoromethyl) -7, 8-dihydro-[1, 2, 4]triazolo[4, 3-b]pyridazin-6-yl) piperidin-4-yl) phenoxy) ethyl) piperazin-1-yl) ethanone; 6- (4-{4- [2- (4-acetylpiperazin-1-yl) ethoxy] phenyl}piperidin-1-yl) -3- (trifluoromethyl) -7, 8-dihydro [1, 2, 4] triazolo [4, 3-b] pyridazine. Grades: Highly Purified. CAS No. 1240299-33-5. Pack Sizes: 10mg, 25mg. Molecular Formula: C25H32F3N7O2, Molecular Weight: 519.56. US Biological Life Sciences. | Worldwide |
| AZD-3514 | AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer. Synonyms: AZD3514; AZD 3514; AZD-3514. Grades: 0.98. CAS No. 1240299-33-5. Molecular formula: C25H32F3N7O2. Mole weight: 519.56. | |
| AZD3759 | AZD3759 is a n orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3759 binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. Synonyms: AZD3759; AZD-3759; AZD 3759. Grades: 98%. CAS No. 1626387-80-1. Molecular formula: C22H23ClFN5O3. Mole weight: 459.91. | |
| AZD-3759 hydrochloride | AZD-3759 hydrochloride is an effective, orally active and central nervous system-penetrant EGFR inhibitor. AZD-3759 hydrochloride induces cancer cell apoptosis. Synonyms: AZD3759 hydrochloride; Zorifertinib HCl; Zorifertinib hydrochloride; (R)-4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride. CAS No. 1626387-81-2. Molecular formula: C22H24Cl2FN5O3. Mole weight: 496.36. | |
| AZD3839 | AZD3839, also called CHEMBL2177913, as a potent BACE1 inhibitor it is a clinical candidate for the treatment of Alzheimer's disease. Studies indicate that the inhibition of BACE1 impedes the production of Aβ peptide. Synonyms: AZD3839; AZD-3839; AZD 3839. (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine; CHEMBL2177913; I8ID590133; UNII-I8ID590133; I8ID590133; SCHEMBL1358337; BDBM50398264; (1S)-1-(2-(Difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine; 1227163-84-9; 1H-Isoindol-3-amine, 1-(2-(difluoromethyl)-4-pyridinyl)-4-fluoro-1-(3-(5-pyrimidinyl)phenyl)-, (1S)-. CAS No. 1227163-84-9. Molecular formula: C24H16F3N5. Mole weight: 431.41. | |
| AZD3839 free base | AZD3839 free base is a potent and selective orally active, brain-permeable BACE1 inhibitor ( K i=26 nM). AZD3839 free base shows 14 and >1000-fold selectivity against BACE2 and cathepsin D, respectively. AZD3839 free base exhibits dose- and time-dependent lowering of plasma, brain, and cerebrospinal fluid Aβ levels in mouse, guinea pig, and non-human primate. AZD3839 free base can be used for the research of Alzheimer's disease [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1227163-84-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-13438. | |
| AZD3965 | AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, which is 6-fold selective over MCT2 and does not inhibit MCT4 at 10 μM. Both lactate transport and cell growth are potently inhibited by AZD3965 in lymphoma cell lines that preferentially express MCT1. Lactate transport inhibition in some cell lines also induces a cytotoxic effect. In vitro combination studies show that lactate transport inhibition can enhance the induction of cell death by doxorubicin. Blocking lactate transport in vitro also leads to a rapid inhibition of glucose uptake in the Raji Burkitt's lymphoma cell line. In vivo, AZD3965 is well tolerated and induces a dose- and time-dependent accumulation of lactate in the tumors, suppresses tumor growth and in the Raji model potentiates the effects of Rituxan, doxorubicin and bendamustine. The selective inhibition of lactate transport by the MCT1 inhibitor AZD3965 offers a novel mechanism for targeting the metabolic phenotype in tumors that preferentially express MCT1. Synonyms: (S)-5-(4-hydroxy-4-methylisoxazolidine-2-carbonyl)-1-isopropyl-3-methyl-6-((3-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione; AZD3965; AZD-3965; AZD 3965. Grades: >98%. CAS No. 1448671-31-5. Molecular formula: C21H24F3N5O5S. Mole weight: 515.51. | |
| AZD3965 | AZD3965 is a selective MCT1 inhibitor with a K i of 1.6 nM, showing 6-fold selectivity over MCT2. Uses: Scientific research. Group: Signaling pathways. CAS No. 1448671-31-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-12750. | |
| AZD3965 | AZD3965 Inhibitor. Uses: Scientific use. Product Category: T3210. CAS No. 1448671-31-5. | |
| AZD 3988 | AZD 3988 is a selective and potent diacylglycerol O-acyltransferase (DGAT) enzyme inhibitor with IC50 value of 0.6 nM. It is selective for DGAT-1 over DGAT-2, cytochrome P450 enzymes and Kv11.1 (hERG). It suppresses adipose tissue TAG synthesis and triacylglyceride (TAG) plasma excursion in rats. It reduces body weight of diet-induced obese rats and may be used as a potential treatment for diabetes and other metabolic diseases. It is orally bioavailable and cell permeable. Synonyms: AZD 3988; AZD-3988; AZD3988; trans-4- [- [ [ [5- [ (3, 4-Difluorophenyl) amino] -1, 3, 4-oxadiazol-2-yl] carbonyl] amino] phenyl] cyclohexaneacetic acid. Grades: ≥98% by HPLC. CAS No. 892489-52-0. Molecular formula: C23H22F2N4O4. Mole weight: 456.44. | |
| AZD4017 | AZD4017 is a potent, selective, and orally bioavailable 11β-HSD1 inhibitor (11β-hydroxysteroid dehydrogenase type 1 inhibitor). Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Synonyms: AZD-4017; AZD 4017; (S)-2-(1-(5-(Cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid. Grades: 96%. CAS No. 1024033-43-9. Molecular formula: C22H33N3O3S. Mole weight: 419.58. | |
| AZD4017 | AZD4017 is a potent, selective, and orally bioavailable11β-HSD1 inhibitor (11β-hydroxysteroid dehydrogenase type 1 inhibitor). Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. AZD4017 is a nicotinic amide derived carboxylic acid class of inhibitors that has good potency, selectivity, and pharmacokinetic characteristics. AZD4017) is an effective inhibitor of 11β-HSD1 in human adipocytes and exhibits good druglike properties and as a consequence was selected for clinical development. Uses: Designed for use in research and industrial production. Additional or Alternative Names: AZD4017; AZD-4017; AZD 4017. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1024033-43-9. Molecular formula: C22H33N3O3S. Mole weight: 419.58. Purity: >98%. IUPACName: 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid. Canonical SMILES: O=C(O)C[C@H]1CN(C2=NC(SCCC)=C(C(NC3CCCCC3)=O)C=C2)CCC1. Product ID: ACM1024033439. Alfa Chemistry ISO 9001:2015 Certified. |  |
| AZD4320 | AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC 50 s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1357576-48-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-112416. | |
| AZD-4320 | AZD-4320 is a new type of BH3 analogue BCL2/BCLxL dual inhibitor. Synonyms: AZD4320. Grades: ≥98% by HPLC. CAS No. 1357576-48-7. Molecular formula: C45H48ClF3N4O7S3. Mole weight: 945.5. | |
| AZD-4547 | AZD4547 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. Synonyms: AZD-4547; AZD 4547; AZD4547; N-{3-[2-(3,5-Dimethoxyphenyl)ethyl]-1h-Pyrazol-5-Yl}-4-[(3r,5s)-3,5-Dimethylpiperazin-1-Yl]benzamide. Grades: 98%. CAS No. 1035270-39-3. Molecular formula: C26H33N5O3. Mole weight: 463.582. | |
| AZD4573 | AZD-4573 (AZD4573) is a potent and selective inhibitor of CDK9, with fast-off binding kinetics and high selectivity versus other kinases. AZD4573 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II, leading to the inhibition of gene transcription of various anti-apoptotic proteins. Synonyms: AZD-4573; AZD 4573; (1S,3R)-3-acetamido-N-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexane-1-carboxamide. Grades: ≥98%. CAS No. 2057509-72-3. Molecular formula: C22H28ClN5O2. Mole weight: 429.94. | |
| AZD4573 | AZD4573 is a potent and highly selective CDK9 inhibitor ( IC 50 of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2057509-72-3. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-112088. | |
| AZD-4635 | AZD-4635 is an orally available adenosine 2A receptor (A2AR) inhibitor. Synonyms: AZD-4635; AZD 4635; AZD4635; HTL-1071; HTL 1071; HTL1071; 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine. CAS No. 1321514-06-0. Molecular formula: C15H11ClFN5. Mole weight: 315.736. | |
| AZD-4694 | AZD-4694 is a bio-active chemical compound and is used as a diagnostic imaging agent. It was developed by AstraZeneca. Synonyms: AZD 4694; AZD-4694; AZD4694; NAV4694; NAV 4694; NAV-4694; Flutafuranol; 2-(2-Fluoro-6-methylaminopyridin-3-yl)benzofuran-5-ol. Grades: >98%. CAS No. 1054629-49-0. Molecular formula: C14H11FN2O2. Mole weight: 258.25. | |
| AZD4694 Precursor | AZD4694 Precursor (AZ13040214) is the precursor of [ 18 F] AZD4694 for the synthesis of [ 18 F] AZD4694, an amyloid-β imaging ligand with high affinity for amyloid-β plaques [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AZ13040214; NAV4614. CAS No. 1211333-20-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139516. | |
| AZD-4818 | AZD-4818 is a chemokine CCR1 antagonist that is used for the treatment of chronic obstructive pulmonary disease. Uses: Designed for use in research and industrial production. Additional or Alternative Names: AZD-4818; AZD 4818; AZD4818. Product Category: Antagonists. Appearance: Solid powder. CAS No. 1003566-93-5. Molecular formula: C27H32Cl2N2O7. Mole weight: 567.46. Purity: >98%. IUPACName: (S)-2-(2-chloro-5-(3-(5-chloro-3H-spiro[benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropoxy)-4-(methylcarbamoyl)phenoxy)-. Canonical SMILES: CC(C)(OC1=CC(OC[C@@H](O)CN2CCC3(CC2)OC4=CC=C(Cl)C=C4C3)=C(C(NC)=O)C=C1Cl)C(O)=O. Product ID: ACM1003566935. Alfa Chemistry ISO 9001:2015 Certified. | |
| AZD4877 | AZD4877 is a synthetic kinesin spindle protein (KSP) inhibitor with potential antineoplastic activity. AZD4877 selectively inhibits microtubule motor protein KSP (also called kinesin-5 or Eg5), which may result in the inhibition of mitotic spindle assembly. Synonyms: AZD-4877; AZD 4877; (+)-N-(3-Aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide. CAS No. 1176760-49-8. Molecular formula: C28H33N5O2S. Mole weight: 503.66. | |
| AZD-5069 | AZD-5069 is a potent and selective CXCR2 antagonist with the potential to inhibit neutrophil migration into the airways in patients with COPD. AZD-5069 was shown to inhibit binding of radiolabeled CXCL8 to human CXCR2 with a pIC50 value of 9.1. Synonyms: AZD-5069; AZD 5069; AZD5069. Grades: 98%. CAS No. 878385-84-3. Molecular formula: C18H22F2N4O5S2. Mole weight: 476.51. | |
| AZD-5099 | AZD-5099 is a DNA gyrase modulator potentially for the treatment of bacterial infection. Uses: Designed for use in research and industrial production. Additional or Alternative Names: AZD-5099; AZD 5099; AZD5099. Product Category: Others. Appearance: Solid powder. CAS No. 907543-25-3. Molecular formula: C21H27Cl2N5O6S. Mole weight: 548.44. Purity: >98%. IUPACName: 2-((3S,4R)-4-(3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamido)-3-methoxypiperidin-1-yl)-4-(((S)-1-methoxypropan-2-yl)carbamoyl)thiazole-5-carboxylic acid. Canonical SMILES: O=C(C1=C(C(N[C@@H](C)COC)=O)N=C(N2C[C@H](OC)[C@H](NC(C3=C(Cl)C(Cl)=C(C)N3)=O)CC2)S1)O. Product ID: ACM907543253. Alfa Chemistry ISO 9001:2015 Certified. | |
| AZD5153 | AZD5153 (Compound 13) is a trivalent triazolpyrazine bromide domain (BRD), bromodomain and extraterminal (BET) inhibitor. AZD5153 has down-regulated c-Myc gene and tumor growth inhibition activity. AZD5153 can be used in the study of BET small molecule inhibitors [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1869912-39-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg. Product ID: HY-100653. | |
| AZD 5153 | AZD5153 is a potent, selective, and orally available inhibitor of the bromodomain and extraterminal (BET) Inhibitor. It can simultaneously bind two bromodomains in BRD4 with the IC50 value of 5 nM, which has been shown to increase antitumor activity in multiple xenograft models of acute myeloid leukemia, multiple myeloma, and diffuse large B cell lymphoma. AZD5153 also shows enhanced potency as a result of bivalent binding and a clear correlation between BRD4 activity and cellular potency. Synonyms: (3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidinyl]phenoxy]ethyl]-1,3-dimethyl-2-piperazinone; (3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-dimethylpiperazin-2-one. Grades: ≥ 95 %. CAS No. 1869912-39-9. Molecular formula: C25H33N7O3. Mole weight: 479.57. | |
| AZD5153 6-Hydroxy-2-naphthoic acid | AZD5153 6-Hydroxy-2-naphthoic acid, a 6-hydroxy-2-naphthoic acid salt of AZD-5153, is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor possessing a bivalent binding mode (pKi = 8.3 for BRD4). Synonyms: AZD5153 6-Hydroxy-2-naphthoic acid; AZD 5153 6-Hydroxy-2-naphthoic acid; AZD-5153 6-Hydroxy-2-naphthoic acid; 6-hydroxynaphthalene-2-carboxylic acid;4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-dimethylpiperazin-2-one. CAS No. 1869912-40-2. Molecular formula: C36H41N7O6. Mole weight: 667.75. | |
| AZD5153 6-Hydroxy-2-naphthoic acid | AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC 50 of 1.7 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1869912-40-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100653A. | |
| AZD5305 | AZD5305 is a potent, selective and oral active PARP inhibitor. AZD5305 is a highly potent inhibitor of PARP1, with significant PARP1-DNA trapping activity, no PARP2-activity, nor binding activity to any other members of the PARP family. AZD5305 has excellent secondary pharmacology and physicochemical properties as well as high oral bioavailability in preclinical species. Uses: Designed for use in research and industrial production. Additional or Alternative Names: AZD5305; AZD-5305; AZD 5305. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 2589531-76-8. Molecular formula: C22H26N6O2. Mole weight: 406.49. Purity: >98%. IUPACName: 5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpicolinamide. Canonical SMILES: O=C(C1=NC=C(N2CCN(CC3=CC(N4)=C(N=C3)C=C(CC)C4=O)CC2)C=C1)NC. Product ID: ACM2589531768. Alfa Chemistry ISO 9001:2015 Certified. Categories: AZD1305. | |
| AZD 5363 | AZD5363 is used in inhibiting the proliferation of certain tumor cell lines. Inhibits AKT1, AKT2, AKT3, P70S6K and PKA. Group: Biochemicals. Grades: Highly Purified. CAS No. 1143532-39-1. Pack Sizes: 1mg, 5mg. Molecular Formula: C21H25ClN6O2, Molecular Weight: 428.95. US Biological Life Sciences. | Worldwide |
| AZD-5363 | AZD-5363 is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AZD-5363 binds to and inhibits all AKT isoforms. This agent may be used as monotherapy or combination therapy for a variety of human cancers. Synonyms: AZD5363; AZD 5363; Capivasertib. Grades: 98%. CAS No. 1143532-39-1. Molecular formula: C21H25ClN6O2. Mole weight: 428.9152. | |
| AZD5423 | AZD5423 is an inhaled, potent, selective, and non-steroidal glucocorticoid receptor (GR) modulator (SGRM) [1]. AZD5423 effectively reduces allergen-induced responses in subjects with mild allergic asthma [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1034148-04-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108243. | |
| AZD-5423 | AZD-5423 is a nonsteroidal glucocorticoid. It is used to treat respiratory diseases and in particular chronic obstructive pulmonary disease. It was developed by AstraZeneca. Uses: Azd-5423 is used to treat respiratory diseases and in particular chronic obstructive pulmonary disease. Synonyms: AZD-5423; AZD 5423; AZD5423; UNII-641H0Q518W; 2,2,2-Trifluoro-N-((1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-methoxyphenyl)-2-propanyl)acetamide. Grades: >98 %. CAS No. 1034148-04-3. Molecular formula: C25H21F4N3O3. Mole weight: 487.45. | |
Our database is helping our users find suppliers everyday.
